Related Experiment Video

Updated: Jun 2, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

The emergence of designed multiple ligands for neurodegenerative disorders

Werner J Geldenhuys1, Moussa B H Youdim, Richard T Carroll

  • 1Department of Pharmaceutical Sciences, Northeast Ohio Medical University (NEOMED), 4209 State Route 44, Rootstown, OH 44272, USA.

Progress in Neurobiology
|May 4, 2011
PubMed

Insights

Multifunctional drugs targeting complex neurodegenerative diseases show promise. These designed multiple ligands (DMLs) offer better outcomes than single-target drugs in preclinical studies for conditions like Alzheimer's and Parkinson's disease.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Neurodegenerative diseases are increasing globally due to longer life expectancy.
  • Current treatments are limited, with few disease-modifying therapies available.
  • The complex and heterogeneous nature of these diseases makes single-target drugs less effective.

Purpose of the Study:

  • To review the rationale for developing multifunctional drugs (designed multiple ligands or DMLs).
  • To discuss why DMLs may offer better outcomes than single-target drugs for neurodegenerative diseases.
  • To highlight examples of DMLs in preclinical and clinical development.

Main Methods:

  • Literature review of peer-reviewed articles on drug design and discovery for neurodegenerative diseases.
  • Analysis of preclinical and clinical data for single-targeted versus multifunctional drug candidates.
  • Discussion of the complex pathophysiology of neurodegenerative diseases.

Main Results:

  • Multifunctional drugs (DMLs) are emerging as a promising strategy for complex diseases.
  • Preclinical studies suggest DMLs may outperform single-targeted drugs for Alzheimer's and Parkinson's disease.
  • The review covers successful, unsuccessful, and pipeline DML candidates.

Conclusions:

  • The complexity of neurodegenerative diseases necessitates a move towards multifunctional drug development.
  • Designed multiple ligands (DMLs) represent a rational approach to address multiple targets in disease pathways.
  • Further research and development of DMLs are crucial for advancing treatment options for neurodegenerative disorders.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Ligand-gated Ion Channels01:19

Ligand-gated Ion Channels

Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...